
Sign up to save your podcasts
Or
Faça sua pré-inscrição nesse link https://www.tadeclinicagem.com.br/materiais/antibiotico-lead-cistite/ e tenha acesso gratuito a aula de cistite.
.
Rapha, Leticia e Lucca discutem 7 armadilhas na doença do refluxo gastroesofageana (DRGE)!
🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨
Referências:
1. Fass, Ronnie. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 387,13 (2022): 1207-1216.
2. Parmar, Malvinder S. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 388,9 (2023): 863.
3. Jenkins, Danny, and Ines Modolell. “Proton pump inhibitors.” BMJ (Clinical research ed.) vol. 383 e070752. 13 Nov. 2023.
4. Katzka, David A, and Peter J Kahrilas. “Advances in the diagnosis and management of gastroesophageal reflux disease.” BMJ (Clinical research ed.) vol. 371 m3786. 23 Nov. 2020,
5. Barr J, Gulrajani NB, Hurst A, Pappas TN. Bottoms Up: A History of Rectal Nutrition From 1870 to 1920. Ann Surg Open. 2021;2(1):e039. Published 2021 Feb 10.
6.Fass, R et al. “Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.” Alimentary pharmacology & therapeutics vol. 29,12 (2009): 1261-72.
7. Lee, R. D., et al. "Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor–evidence for dosing flexibility." Alimentary pharmacology & therapeutics 29.8 (2009): 824-833.
8.Metz, D C et al. “Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.” Alimentary pharmacology & therapeutics vol. 29,7 (2009): 742-54.
9. Ip, Stanley, et al. Comparative Effectiveness of Management Strategies For Gastroesophageal Reflux Disease. Agency for Healthcare Research and Quality (US), December 2005.
10. Zhuang, Qianjun, et al. "Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis." Official journal of the American College of Gastroenterology| ACG (2022): 10-14309.
11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020839s078lbl.pdf
15. Chen, Joan W., et al. "AGA clinical practice update on the diagnosis and management of extraesophageal gastroesophageal reflux disease: expert review." Clinical Gastroenterology and Hepatology (2023).
5
55 ratings
Faça sua pré-inscrição nesse link https://www.tadeclinicagem.com.br/materiais/antibiotico-lead-cistite/ e tenha acesso gratuito a aula de cistite.
.
Rapha, Leticia e Lucca discutem 7 armadilhas na doença do refluxo gastroesofageana (DRGE)!
🚨 www.tadeclinicagem.com.br/guia - Conheça o Guia TdC com 7 dias grátis 🚨
Referências:
1. Fass, Ronnie. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 387,13 (2022): 1207-1216.
2. Parmar, Malvinder S. “Gastroesophageal Reflux Disease.” The New England journal of medicine vol. 388,9 (2023): 863.
3. Jenkins, Danny, and Ines Modolell. “Proton pump inhibitors.” BMJ (Clinical research ed.) vol. 383 e070752. 13 Nov. 2023.
4. Katzka, David A, and Peter J Kahrilas. “Advances in the diagnosis and management of gastroesophageal reflux disease.” BMJ (Clinical research ed.) vol. 371 m3786. 23 Nov. 2020,
5. Barr J, Gulrajani NB, Hurst A, Pappas TN. Bottoms Up: A History of Rectal Nutrition From 1870 to 1920. Ann Surg Open. 2021;2(1):e039. Published 2021 Feb 10.
6.Fass, R et al. “Clinical trial: the effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with non-erosive reflux disease.” Alimentary pharmacology & therapeutics vol. 29,12 (2009): 1261-72.
7. Lee, R. D., et al. "Clinical trial: the effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor–evidence for dosing flexibility." Alimentary pharmacology & therapeutics 29.8 (2009): 824-833.
8.Metz, D C et al. “Clinical trial: dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis.” Alimentary pharmacology & therapeutics vol. 29,7 (2009): 742-54.
9. Ip, Stanley, et al. Comparative Effectiveness of Management Strategies For Gastroesophageal Reflux Disease. Agency for Healthcare Research and Quality (US), December 2005.
10. Zhuang, Qianjun, et al. "Comparative efficacy of P-CABs versus proton pump inhibitors for Grade C/D esophagitis: A systematic review and network meta-analysis." Official journal of the American College of Gastroenterology| ACG (2022): 10-14309.
11. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020839s078lbl.pdf
15. Chen, Joan W., et al. "AGA clinical practice update on the diagnosis and management of extraesophageal gastroesophageal reflux disease: expert review." Clinical Gastroenterology and Hepatology (2023).
304 Listeners
19 Listeners
63 Listeners
4 Listeners
8 Listeners
45 Listeners
27 Listeners
210 Listeners
30 Listeners
0 Listeners
1 Listeners
6 Listeners
12 Listeners
14 Listeners
4 Listeners